Tag Archive for: bispecific antibody
Nezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: GEN1057 Bispecific-Antibody In Metastatic Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial for ASP1002, a bispecific antibody
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAPVO442: A Promising New Bispecific Antibody for Prostate Cancer Treatment
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- New Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models August 9, 2025
- Phase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC) August 8, 2025
- Phase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC August 8, 2025
- Phase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC August 8, 2025